229 related articles for article (PubMed ID: 16098076)
1. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
[TBL] [Abstract][Full Text] [Related]
2. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
3. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
Lauter A; Strumpf A; Platzbecker U; Schetelig J; Wermke M; Radke J; Kiani A; Wunderlich G; Thiede C; Ehninger G; Kotzerke J; Bornhäuser M
Br J Haematol; 2010 Mar; 148(6):910-7. PubMed ID: 19995390
[TBL] [Abstract][Full Text] [Related]
4. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
7. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
8. [Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
Mutschler J; Steinbach G; Bunjes D; Reske SN; Buchmann I
Nuklearmedizin; 2009; 48(1):30-6. PubMed ID: 19212609
[TBL] [Abstract][Full Text] [Related]
9. Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Schneider S; Strumpf A; Schetelig J; Wunderlich G; Ehninger G; Kotzerke J; Bornhäuser M
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1754-60. PubMed ID: 26001695
[TBL] [Abstract][Full Text] [Related]
10. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
[TBL] [Abstract][Full Text] [Related]
11. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
12. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
[TBL] [Abstract][Full Text] [Related]
14. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.
Bunjes D
Leuk Lymphoma; 2002 Nov; 43(11):2125-31. PubMed ID: 12533037
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Zenz T; Schlenk RF; Glatting G; Neumaier B; Blumstein N; Buchmann I; von Harsdorf S; Ringhoffer M; Wiesneth M; Keller F; Kotzerke J; Röttinger E; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
J Nucl Med; 2006 Feb; 47(2):278-86. PubMed ID: 16455634
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
17. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Bunjes D; Buchmann I; Duncker C; Seitz U; Kotzerke J; Wiesneth M; Dohr D; Stefanic M; Buck A; Harsdorf SV; Glatting G; Grimminger W; Karakas T; Munzert G; Döhner H; Bergmann L; Reske SN
Blood; 2001 Aug; 98(3):565-72. PubMed ID: 11468151
[TBL] [Abstract][Full Text] [Related]
18. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
Zenz T; Glatting G; Schlenk RF; Buchmann I; Döhner H; Reske SN; Bunjes D
Haematologica; 2006 Feb; 91(2):285-6. PubMed ID: 16461327
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Guo M; Yu CL; Wang DH; Qiao JH; Sun WJ; Shi BF; Zhang S; Sun QY; Yao B; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):413-5. PubMed ID: 14642178
[TBL] [Abstract][Full Text] [Related]
20. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
